Penta Valent
PT. Penta Valent Tbk distributes pharmaceutical products, medical equipment, and consumer products in Indonesia. It operates through Pharmaceutical Products and Consumer Goods segments. The company offers prescription medicinal products; over the counter drug products; medical supporting equipment, such as blood pressure meters, body thermometers, and others; reaction materials, such as blood sug… Read more
Penta Valent (PEVE) - Net Assets
Latest net assets as of September 2025: Rp331.20 Billion IDR
Based on the latest financial reports, Penta Valent (PEVE) has net assets worth Rp331.20 Billion IDR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rp1.32 Trillion) and total liabilities (Rp983.83 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rp331.20 Billion |
| % of Total Assets | 25.19% |
| Annual Growth Rate | 39.79% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 17.29 |
Penta Valent - Net Assets Trend (2022–2024)
This chart illustrates how Penta Valent's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Penta Valent (2022–2024)
The table below shows the annual net assets of Penta Valent from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Rp286.99 Billion | +23.59% |
| 2023-12-31 | Rp232.21 Billion | +58.18% |
| 2022-12-31 | Rp146.80 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Penta Valent's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 346.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rp108.45 Billion | 37.79% |
| Common Stock | Rp35.31 Billion | 12.30% |
| Other Components | Rp143.23 Billion | 49.91% |
| Total Equity | Rp286.99 Billion | 100.00% |
Penta Valent Competitors by Market Cap
The table below lists competitors of Penta Valent ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
068100
KQ:068100
|
$9.95 Million |
|
Aiptek International Inc
TW:6225
|
$9.95 Million |
|
OVB Holding AG
XETRA:O4B
|
$9.95 Million |
|
Tecnisa S.A
SA:TCSA3
|
$9.95 Million |
|
GCM Resources Plc
PINK:GCLMF
|
$9.94 Million |
|
SETANTA A-E ZY -10
F:SE2
|
$9.94 Million |
|
Manaksia Steels Limited
NSE:MANAKSTEEL
|
$9.94 Million |
|
Xreality Group Ltd
AU:XRG
|
$9.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Penta Valent's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 232,208,991,040 to 286,994,018,790, a change of 54,785,027,750 (23.6%).
- Net income of 48,011,814,860 contributed positively to equity growth.
- Other factors increased equity by 6,773,212,890.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rp48.01 Billion | +16.73% |
| Other Changes | Rp6.77 Billion | +2.36% |
| Total Change | Rp- | 23.59% |
Book Value vs Market Value Analysis
This analysis compares Penta Valent's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.06x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 5.99x to 3.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | Rp83.14 | Rp498.00 | x |
| 2023-12-31 | Rp131.52 | Rp498.00 | x |
| 2024-12-31 | Rp162.55 | Rp498.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Penta Valent utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.73%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.59%
- • Asset Turnover: 2.59x
- • Equity Multiplier: 4.05x
- Recent ROE (16.73%) is above the historical average (16.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 16.04% | 1.10% | 2.89x | 5.07x | Rp8.87 Billion |
| 2023 | 15.58% | 1.46% | 2.74x | 3.90x | Rp12.95 Billion |
| 2024 | 16.73% | 1.59% | 2.59x | 4.05x | Rp19.31 Billion |
Industry Comparison
This section compares Penta Valent's net assets metrics with peer companies in the Pharmaceutical Retailers industry.
Industry Context
- Industry: Pharmaceutical Retailers
- Average net assets among peers: $123,738,880,680
- Average return on equity (ROE) among peers: 14.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Penta Valent (PEVE) | Rp331.20 Billion | 16.04% | 2.97x | $9.94 Million |
| Ikapharmindo Putramas Tbk. (IKPM) | $246.12 Billion | 2.04% | 1.00x | $4.43 Million |
| Multi Medika Internasional (MMIX) | $1.35 Billion | 26.08% | 1.40x | $15.50 Million |